Second, is lymphotoxin beta receptor, which like many of Biogen's products is aimed at fixing faults in the immune system that can lead to autoimmune and inflammatory diseases. The way to get at these undertreated or untreated portions has got to be with a drug with a new mechanism of action. That is what Antegren provides. Biogen is also focused on technologies realized by the human genome project. We've put ourselves in a sweet spot to go forward aggressively in the business development area.
Investors have to be sure a company is acting on a strategy and one that is likely to be successful.
If we went back to the beginning of 2000 there may not have been enough evidence for them to be convinced of that. I think we have that evidence now. Inc. All Rights Reserved. Please read our Disclaimer , Trademarks , and Privacy Statement .